KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $0.41.

  • Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted) rose 31578.95% to $0.41 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2, marking a year-over-year increase of 18275.86%. This contributed to the annual value of $1.21 for FY2025, which is 18344.83% up from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted) is $0.41, which was up 31578.95% from $0.37 recorded in Q3 2025.
  • Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.41 during Q4 2023, with a 5-year trough of -$1.92 in Q4 2022.
  • Its 5-year average for EPS (Weighted Average and Diluted) is -$0.21, with a median of -$0.04 in 2024.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted) crashed by 132857.14% in 2022, and later skyrocketed by 31578.95% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted) stood at -$1.01 in 2021, then crashed by 90.0% to -$1.92 in 2022, then skyrocketed by 121.39% to $0.41 in 2023, then crashed by 146.34% to -$0.19 in 2024, then skyrocketed by 315.79% to $0.41 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at $0.41 for Q4 2025, versus $0.37 for Q3 2025 and $0.24 for Q2 2025.